Exploring the Global Growth Opportunities in Booming Peptide Synthesis Market

In recent years, peptides have become the cornerstone of numerous medical and biotechnological advancements. These short chains of amino acids play crucial roles in various biological functions and have found their way into therapeutic drugs, diagnostics, and research tools. The global peptide synthesis market is riding this wave of innovation, poised to grow from USD 601 million in 2023 to USD 859 million by 2028, at a CAGR of 7.4%. Let’s delve into the key drivers, segments, and future prospects of this dynamic market.

Key Drivers of Market Growth:

The growth of the peptide synthesis market can be attributed to several critical factors:

# Increasing Demand for Peptides: Peptides are increasingly used in pharmaceuticals due to their high specificity and potency, low toxicity, and ability to target a wide range of diseases.
# Technological Advancements: Innovations in synthesis technologies, such as solid-phase and hybrid techniques, have streamlined the production process, making it more efficient and cost-effective.
# Expanding Therapeutic Applications: Peptides are being explored for treating various conditions, including cancer, metabolic disorders, and infectious diseases.
# Rising R&D Investments: Significant investments in research and development are driving advancements in peptide therapeutics and synthesis methodologies.
# Supportive Market Ecosystem: The growth of contract research and manufacturing organizations (CROs and CMOs) has bolstered the market, providing essential services to biotech and pharma companies.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

Market Segmentation:

The peptide synthesis market is segmented based on product & service, technology, end user, and region. Here’s a closer look at these segments:

Product & Service:

# Reagents: The reagents segment, including resins, amino acids, and dyes, accounted for the largest share of the market in 2022. This is driven by the high demand for peptide-based therapeutics and the availability of diverse synthesis reagents.
# Equipment: This includes peptide synthesizers, chromatography systems, and lyophilizers. Advances in automation and technology have made equipment more efficient, though high costs remain a challenge.
# Services: Outsourcing synthesis to specialized firms provides flexibility and access to advanced technologies without significant capital investment.

Technology:

# Solid-Phase Peptide Synthesis (SPPS): Dominating the market, SPPS offers numerous advantages such as ease of operation, automation potential, and the ability to produce long peptides efficiently.
# Solution-Phase Peptide Synthesis: While less common, this method is used for specific applications where SPPS may not be suitable.
# Hybrid & Recombinant Technologies: Combining the best of both worlds, these technologies are gaining traction for their versatility and efficiency.

End User:

# Pharmaceutical and Biotechnology Companies: These entities are the primary consumers of peptide synthesis products and services, driving innovation and development.
# Contract Research Organizations (CROs): CROs are essential partners in research and drug development, providing expertise and resources.
# Academic and Research Institutions: These institutions contribute significantly to the advancement of peptide science through fundamental research.

Regional Insights:

Geographically, the peptide synthesis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

# North America: Holding the largest market share, North America's growth is driven by substantial R&D investments and a robust pharmaceutical industry.
# Asia Pacific: Expected to grow at the highest CAGR, this region benefits from rising R&D expenditure, increasing prevalence of chronic diseases, and significant investments in drug discovery and development.
# Europe, Latin America, and the Middle East & Africa: These regions also show promising growth, with expanding biotech sectors and supportive regulatory environments.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

Leading Market Players:

Prominent companies shaping the peptide synthesis market include

# Thermo Fisher Scientific, Inc. (US)
# Merck KGaA (Germany)
# Kaneka Corporation (Japan)
# GenScript Biotech Corporation (China)
# Bachem Holding AG (Switzerland)

These companies are at the forefront of innovation, driving the market with new technologies, products, and services.

Conclusion:

The peptide synthesis market is on a robust growth trajectory, underpinned by technological advancements, increasing demand for peptide-based therapeutics, and substantial R&D investments. As the market continues to evolve, it promises to play a pivotal role in the future of medicine, offering new possibilities for treatment and research. Stakeholders across the pharmaceutical, biotech, and research sectors will find ample opportunities to innovate and grow in this dynamic landscape.

Related Studies:

Peptide Synthesis Market – Revenue Growth Trends by 2028
https://www.marketsandmarketsblog.com/peptide-synthesis-market-revenue-growth-trends-by-2028.html

Peptide Synthesis Market worth $859 million | MarketsandMarkets
https://www.prnewswire.com/news-releases/peptide-synthesis-market-worth-859-million--marketsandmarkets-301874015.html

Peptide Synthesis Market - Revenue Growth Trends by 2028

Major Growth Driving Factors:

Over the course of the forecast period, the global market for peptide synthesis is anticipated to expand at a CAGR of 7.4%. The expanding therapeutic applications, technological advancements in peptide synthesis, and rising peptide demand are driving growth in this market. In addition, increased spending on R&D, a thriving industry, and the use of peptides in pharmaceutical products are some of the key factors expected to propel market expansion. Nonetheless, over the course of the forecast period, the absence of a single set of regulations pertaining to therapeutic peptides and the high cost of instruments are anticipated to impede the market's growth.

Driver: Peptides are being used in pharmaceutical products more often.

Peptides are very specific and very active pharmaceutical ingredients. They have a wide range of therapeutic applications because of the diversity of their biological functions. Because of their wide molecular space, high biological activity, high specificity, ease of synthesis, accessibility, and low toxicity, peptides are making their way into the drug development process as possible active pharmaceutical ingredients.

Because of their therapeutic potential, high specificity and low toxicity, versatility and diversity, improvements in peptide synthesis technologies, potential use as drug candidates, emergence of personalized medicine, and rising interest in and funding for peptide-based therapeutics, peptides are becoming more and more common in the pharmaceutical industry. All of these elements work together to make peptides a more valuable class of molecules in the creation of innovative and focused pharmaceutical treatments.

Opportunity: Creation of personalized medicines

The peptide synthesis industry has significant growth opportunities due to the emergence of personalized medicine. Peptides provide the necessary targeting, customization, and specificity to enable individualized treatment plans. It is anticipated that the need for peptide synthesis technologies, services, and products will increase dramatically as personalized medicine continues to develop and gain popularity.

Download PDF Brochure to Read More@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

Restraint: High cost of instruments

The synthesis of proteins involves the use of rapid, high-throughput systems. Peptide synthesizers and chromatography equipment with advanced features and functionalities are generally priced at a premium. Peptide synthesizers are either fully automated, manual, or semi-automated and offer users complete control over the synthesis process. The cost of peptide synthesizers ranges from USD 300,000 to 250,000 based on the automation and advanced features accommodated. Such high prices of instruments make it difficult for developing countries to venture into peptide synthesis.

Challenge: Issues associated with the route of administration of peptide drug

The majority of therapeutic peptides are administered by the parenteral route because of insufficient absorption from the gastrointestinal tract. Peptide drugs are usually indicated for chronic conditions, and the use of injections on a daily basis during long-term treatment has significant drawbacks. In contrast to this inconvenient and potentially problematic method of drug administration, the oral route offers advantages such as self-administration with a high degree of patient acceptability and compliance. The main reasons for the low oral bioavailability of peptide drugs are pre-systemic enzymatic degradation and poor penetration of the intestinal mucosa.

Key Stakeholders:

# Life sciences instrumentation and reagent companies
# Pharmaceutical and biotechnology companies
# Proteomics database and software providers
# Peptide service providers
# Research and consulting firms
# Academic medical centers
# Government research organizations
# Clinical research institutes
# Contract Research Organizations

Market Size Estimation:

A top-down approach was used to estimate and validate the total size of the peptide synthesis market. This method was also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and market have been identified through extensive secondary research
# The revenues generated from the peptide synthesis business of leading players have been determined through primary interviews and secondary research
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Request Sample Pages for more Detailed Information@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

Projected Revenue Growth, Globally:

The global peptide synthesis market in terms of revenue was estimated to be worth $601 million in 2023 and is poised to reach $859 million by 2028, growing at a CAGR of 7.4% from 2023 to 2028.

Geographical Growth Scenario:

Asia Pacific is likely to grow at the highest growth rate during the forecast period.

Based on the region, peptide synthesis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional segment. The Asia Pacific region is estimated to grow at the highest CAGR in the peptide synthesis market during the forecast period. The growth of the pharmaceuticals and life sciences market in the region is primarily driven by the rising R&D expenditure, especially in the area of drug discovery & development, the rising prevalence of chronic disease conditions, and significant investments in the development of therapeutics mAbs.

Peptide Synthesis Market - Future Growth Driving Factors & Surge in Revenue Generation

 Overview of This Study:

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global peptide synthesis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Major Growth Driving Factors:

Growth in this market is driven by the increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced automated peptide synthesizers. However, the lack of a unified set of regulations for therapeutic peptides and the high cost of instruments are expected to restrain the growth of this market during the forecast period.

COVID-19 impact on the Peptide Synthesis Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic. The COVID-19 pandemic has increased the burden on healthcare systems across the globe. According to the WHO, there were 271,963,258 confirmed cases of COVID-19, including 5,331,019 deaths (as of December 17, 2021). The highest number of deaths was in the Americas, followed by Europe and Southeast Asia.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

Research Methodologies Followed for This Study:

Primary Research:

Extensive primary research was conducted after acquiring basic knowledge about the global peptide synthesis market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as personnel from pharmaceutical and biopharmaceutical industries, CDMOs and CROs, academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners.

These interviews were conducted across four major regions, including North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Secondary Research:

The secondary sources referred to for this research study include publications from government sources, such as Association of Biomolecular Resource Facilities, Journal of the American Chemical Society, American Peptide Society, Australian Peptide Association, European Peptide Society, Indian Peptide Society, Protein Science Society of Japan (PSSJ), American Peptide Society (APS), National Institutes of Health (NIH), and World Health Organization (WHO). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global peptide synthesis market, which was validated through primary research.

OPPORTUNITY: Development of personalized medicines

Interest in personalized treatment has been fueled by the concept of tailored therapy with the best response and highest safety margin to ensure better patient care. Proteomic analysis is an attractive and powerful tool for characterizing the molecular profiles of various tissues, either in the normal or diseased state. Personalized proteomics or proteomic profiling is the next big step in personalized medicine; it provides clarity on disease pathomechanisms.

To boost the use of proteomics in personalized medicine, scientists proposed the development of a user-friendly platform to program electrochemically directed peptide synthesis based on a microfluidic multiplexing system controlled by software under the ElectroMed project funded by the European Union. The ligand-receptor complexes will then be detected and quantified by label-free sensors based on nanomaterials.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

Projected Revenue Surge:

The global peptide synthesis market is projected to USD 730 million by 2026 from USD 515 million in 2021, at a CAGR of 7.2% between 2021 and 2026.

Geographical Growth Dynamics:

North Americawas the largest regional market forPeptide SynthesisMarketin 2020.

The peptide synthesis market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 37.6% of the peptide synthesis market, followed by Europe and the Asia Pacific with shares of 29.8% and 26%, respectively.

The large share of North America in the global market can be attributed to the increasing life science R&D, high prevalence of chronic diseases, increasing investments in the development of structure-based drug designs, growing research in the fields of genomics and proteomics, and increasing focus on developing personalized therapeutics. The US held the largest share of the North American Market in 2020. The large share of the US is primarily attributed to increasing life science research activities in the US and the growing prevalence of cancer and chronic diseases.

Peptide Synthesis Market worth $730 million by 2026

 Overview:

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global Peptide Synthesis Market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Major Growth Influencing Factors:

Growth in this market is driven by the increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced automated peptide synthesizers. However, the lack of a unified set of regulations for therapeutic peptides and the high cost of instruments are expected to restrain the growth of this market during the forecast period.

Expected Revenue Growth:

The global peptide synthesis market is projected to USD 730 million by 2026 from USD 515 million in 2021, at a CAGR of 7.2% between 2021 and 2026.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

The reagents segment accounted for the largest share of the product & service segment in the peptide synthesis market in 2020.

Based on product & service, the peptide synthesis market is segmented into reagents, equipment, and services. In 2020, the reagents segment accounted for the largest share of 50.8% of the peptide synthesis market. The large share of this segment can be attributed to the growing applications of peptides in therapeutics, drug design, and gene synthesis; frequent purchase of reagents in comparison to equipment; rising number of ongoing research projects involving peptide synthesis; and the availability of various peptide synthesis reagents in the market.

The Solid Phase peptide synthesis segment accounted for the largest share of the technology segment in the peptide synthesis market in 2020.

Based on technology, the peptide synthesis market is segmented into solid-phase peptide synthesis, solution-phase peptide synthesis, and hybrid & recombinant technology. The solid-phase peptide synthesis segment accounted for the largest share of 62.0% of the peptide synthesis market in 2020. Solid-phase peptide synthesis is associated with several advantages, such as ease of operation, easy purification, short production cycles, high-level automation, and synthesis capabilities of long peptides in small quantities of amino acids. These advantages support the growth of the solid-phase peptide synthesis segment.

The Asia Pacific region is the fastest-growing region of the peptide synthesis market in 2020.

Based on the region, the peptide synthesis market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is expected to register the highest CAGR in the peptide synthesis market during the forecast period. Growing R&D funding, increasing investments by pharmaceutical and biotechnology companies, and rising R&D activities in the region are expected to drive market growth.

Key Players:

Key players in the peptide synthesis market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Kaneka Corporation (Japan), GenScript Biotech Corporation (China), and Bachem Holding AG (Switzerland).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

Peptide Synthesis Market - Development of Personalized Medicines; Major Boon for Global Biotech Industry

 Overview:

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global peptide synthesis market.

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

COVID-19 impact on the Peptide Synthesis Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic. The COVID-19 pandemic has increased the burden on healthcare systems across the globe. According to the WHO, there were 271,963,258 confirmed cases of COVID-19, including 5,331,019 deaths (as of December 17, 2021). The highest number of deaths was in the Americas, followed by Europe and Southeast Asia.

The COVID-19 pandemic has prompted key pharmaceutical and biotechnology companies and players in the peptide synthesis market to invest in therapeutic and peptide-based vaccine R&D. The rising demand for vaccines and peptide-based drugs has brought peptide synthesis to the forefront. The peptide-based approach represents a turning point as peptides have demonstrated unique features of selectivity and specificity towards specific targets.

DRIVER: Increasing use of peptides in pharmaceutical drugs

Peptides are highly active and highly specific drug substances. Due to the diversity of their biological functions, they are used in an extensive range of therapeutic areas. Peptides are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, high biological activity, high specificity, relative ease of synthesis, ready availability, and low toxicity.Oncology, diabetes, and obesity are three prominent therapeutic areas where peptides generate billions of dollars in revenues.

RESTRAINT: Lack of a unified set of regulations for therapeutic peptides

Peptide-based drugs fall in the range of small-molecule and large-molecule biologics. Being at the borderline between typical small molecules and large proteins, peptides have raised a series of regulatory challenges. Most of these drugs are chemically synthesized. Though the synthesis process for different peptide drugs is similar, their action mechanisms vary widely. Hence, developing a unified set of regulatory guidelines that can effectively address the safety and quality requirements for such a diverse group of molecular entities with various unique mechanisms of action is a challenging task. There are no formal guidelines from any regulatory agency for developing this class of therapeutics.

OPPORTUNITY: Development of personalized medicines

Interest in personalized treatment has been fueled by the concept of tailored therapy with the best response and highest safety margin to ensure better patient care. Proteomic analysis is an attractive and powerful tool for characterizing the molecular profiles of various tissues, either in the normal or diseased state. Personalized proteomics or proteomic profiling is the next big step in personalized medicine; it provides clarity on disease pathomechanisms. To boost the use of proteomics in personalized medicine, scientists proposed the development of a user-friendly platform to program electrochemically directed peptide synthesis based on a microfluidic multiplexing system controlled by software under the ElectroMed project funded by the European Union. The ligand-receptor complexes will then be detected and quantified by label-free sensors based on nanomaterials.

Geographical Growth Dynamics: The Asia Pacific region is the fastest-growing region of the peptide synthesis market in 2020.

Based on the region, the peptide synthesis market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is expected to register the highest CAGR in the peptide synthesis market during the forecast period. Growing R&D funding, increasing investments by pharmaceutical and biotechnology companies, and rising R&D activities in the region are expected to drive market growth.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

Global Key Players:

Key players in the peptide synthesis market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Kaneka Corporation (Japan), GenScript Biotech Corporation (China), and Bachem Holding AG (Switzerland).

Peptide Synthesis Market - Global Key Players & Their Dominance in Global Industry

The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period.

The global peptide synthesis market is a fragmented market. GenScript Biotech Corporation (China), Merck KGAA (Germany), AAPPTec (US), Bachem (Switzerland), and Biotage (Sweden) dominated the global peptide synthesis market in 2017.

GenScript Biotech Corporation

GenScript accounted for the largest share of the market in 2017. The company has a broad product/services portfolio in peptide synthesis market and focuses on research and development activities to enhance its offerings. For Instance, in 2016 the company’s research and development expenses were approximately USD 9.5 million, 8.3% of the total revenue. Also during the same year the revenue generated from the life sciences research services segment (that provides peptide synthesis services and products) was approximately USD 91.2 million, representing an increase of 18.6% as compared to approximately USD 76.9 million for 2015.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

Merck KGAA

Merck held the second position in the peptide synthesis market in 2017. The company offers a broad product portfolio of peptide synthesis reagents and custom peptide synthesis services in the market. To leverage growth opportunities in the peptide synthesis market, Merck focuses on adopting organic as well as inorganic growth strategies. For instance, in 2017, the company opened a new Life Science Center in Burlington, Massachusetts (US). The new center serves as a regional hub for scientific advancement and customer collaboration. Also in 2017, the company acquired Grzybowski Scientific Inventions (GSI). This acquisition helped the company to expand its chemical synthesis offering.

Bachem holdings

Bachem is an important player in the peptide synthesis market in 2017. The company offers catalog products that include amino acids, resins, linkers, & reagents. It also offers custom synthesis services in the market. The company aims on broadening its geographic reach by investing in strategic acquisitions, agreements, and collaborations. For instance in 2017, the company has renewed its supply agreement with AstraZeneca for the peptide active substance Goserelin. Also, in 2017 the Bachem Group entered into the collaboration with DOTTIKON ES to bring innovative, new amino acid derivatives for peptide synthesis in the market.

Increasing use of peptides in pharmaceutical drugs drives the global peptide synthesis market

Peptides are highly active and highly specific drug substances. Due to the diversity of their biological functions, they are used in an extensive range of therapeutic areas. Also, they are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, high biological activity, high specificity, relative ease of synthesis, ready availability, and low toxicity.

Oncology, diabetes, and obesity are three prominent therapeutic areas in which peptides generate billions of dollars in revenues. As a drug modality, peptides and peptidomimetics occupy the interface between small molecules and larger biological drugs with the potential to have the specificity of antibodies and the bioavailability of small molecules. Moreover, peptides provide researchers with viable options for discovery, optimization, and manufacture, as they can be synthesized chemically or expressed by recombinant systems. As a result of these advantages, pharmaceutical companies are increasingly focusing on the development of peptide-based drugs.

Pharmaceutical & biotechnological companies are expected to dominate the peptide synthesis market in 2017

Based on end users, the peptide synthesis market is segmented into pharmaceutical & biotechnological companies, contract development and manufacturing organizations, and academic and research institutes. In 2017, pharmaceutical & biotechnological companies accounted for the largest market share due to increasing number of research projects in genomics, molecular biology, and related areas; growing application areas of peptides in drug discovery, therapeutics, and research; and substantial R&D investments.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

APAC is expected to grow at the highest CAGR during the forecast period.

Global peptide synthesis market has been studied for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. APAC is expected to grow at the highest CAGR in the peptide synthesis market, primarily due to the increasing investments by pharmaceutical and biotechnology companies and rising R&D activities in the region.

Peptide Synthesis Market - Emerging Trends to Boost the Global Industry Revenue

 Increasing use of peptides in pharmaceutical drugs drives the global peptide synthesis market

Peptides are highly active and highly specific drug substances. Due to the diversity of their biological functions, they are used in an extensive range of therapeutic areas. Also, they are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, high biological activity, high specificity, relative ease of synthesis, ready availability, and low toxicity.

Oncology, diabetes, and obesity are three prominent therapeutic areas in which peptides generate billions of dollars in revenues. As a drug modality, peptides and peptidomimetics occupy the interface between small molecules and larger biological drugs with the potential to have the specificity of antibodies and the bioavailability of small molecules. Moreover, peptides provide researchers with viable options for discovery, optimization, and manufacture, as they can be synthesized chemically or expressed by recombinant systems. As a result of these advantages, pharmaceutical companies are increasingly focusing on the development of peptide-based drugs.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

Major Objectives of the Study:

# To define, describe, and forecast the peptide synthesis market on the basis of product, technology, end user, and region.

# To provide detailed information about factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).

# To strategically analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of the market segments in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

# To profile key players and comprehensively analyze their market shares and core competencies in the global market.

# To track and analyze competitive developments such as partnerships, agreements, & collaborations; mergers & acquisitions; product developments; and geographical expansions in the global market.

Pharmaceutical & biotechnological companies are expected to dominate the peptide synthesis market in 2017

Based on end users, the peptide synthesis market is segmented into pharmaceutical & biotechnological companies, contract development and manufacturing organizations, and academic and research institutes. In 2017, pharmaceutical & biotechnological companies accounted for the largest market share due to increasing number of research projects in genomics, molecular biology, and related areas; growing application areas of peptides in drug discovery, therapeutics, and research; and substantial R&D investments.

Target Audience:

# Biotechnology & pharmaceutical companies
# Market research and consulting firms
# Venture capitalists and investors
# Research & development companies
# Contract research organizations (CROs)
# Academic research institutes
# Government institutes

APAC is expected to grow at the highest CAGR during the forecast period.

Global peptide synthesis market has been studied for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. APAC is expected to grow at the highest CAGR in the peptide synthesis market, primarily due to the increasing investments by pharmaceutical and biotechnology companies and rising R&D activities in the region.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

Expected Revenue Growth:

The overall peptide synthesis market was valued at USD 292.4 million in 2017 and is projected to reach USD 426.4 million by 2023, at a CAGR of 6.5% during the forecast period. Market growth can be attributed to increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

Global Key Players:

The prominent players in the peptide synthesis market are GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGaA (Germany) and New England Peptide, Inc (US).

Different Growth Strategies Adopted by Them:

Product launches and agreements, partnerships and collaborations were the major strategies adopted by these payers to maintain their positions in the peptide synthesis market.

Peptide Synthesis Market - Emerging Trends & Global Future Forecasts

The overall peptide synthesis market was valued at USD 292.4 million in 2017 and is projected to reach USD 426.4 million by 2023, at a CAGR of 6.5% during the forecast period.

Market growth can be attributed to increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

By technology, solid-phase synthesis is expected to grow at the highest CAGR during 2018-2023

Based on technology, the peptide synthesis market has been segmented into solid-phase synthesis, liquid-phase synthesis and recombinant technology. In 2017, solid-phase synthesis is expected to grow at the highest CAGR during 2018-2023. Solid-phase synthesis is associated with a number of advantages, such as ease of operation, easy purification, short production cycles, high-level automation, and synthesis capabilities of long peptides in small quantities of amino acids. Such advantages are driving the growth of the solid-phase synthesis segment.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

Pharmaceutical & biotechnological companies are expected to dominate the peptide synthesis market in 2017

Based on end users, the peptide synthesis market is segmented into pharmaceutical & biotechnological companies, contract development and manufacturing organizations, and academic and research institutes. In 2017, pharmaceutical & biotechnological companies accounted for the largest market share due to increasing number of research projects in genomics, molecular biology, and related areas; growing application areas of peptides in drug discovery, therapeutics, and research; and substantial R&D investments.

Major Market Developments:

# In 2018, CEM Corporation launched the Liberty PRIME, automated microwave peptide synthesizer.

# In 2017, Merck acquired Grzybowski Scientific Inventions (GSI) (US). This acquisition helped the company to expand its chemical synthesis portfolio.

# In 2015, Merck acquired Sigma-Aldrich Corporation (US). This acquisition strengthened Merck’s Life Science segment. Sigma-Aldrich’s SAFC Commercial business is now a part of Merck’s Life Science segment.

APAC is expected to grow at the highest CAGR during the forecast period.

Global peptide synthesis market has been studied for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. APAC is expected to grow at the highest CAGR in the peptide synthesis market, primarily due to the increasing investments by pharmaceutical and biotechnology companies and rising R&D activities in the region.

Global Leaders:

The prominent players in the peptide synthesis market are GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGaA (Germany) and New England Peptide, Inc (US). Product launches and agreements, partnerships and collaborations were the major strategies adopted by these payers to maintain their positions in the peptide synthesis market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

GenScript Biotech Corporation

GenScript accounted for the largest share of the market in 2017. The company has a broad product/services portfolio in peptide synthesis market and focuses on research and development activities to enhance its offerings. For Instance, in 2016 the company’s research and development expenses were approximately USD 9.5 million, 8.3% of the total revenue.

Merck KGAA

Merck held the second position in the peptide synthesis market in 2017. The company offers a broad product portfolio of peptide synthesis reagents and custom peptide synthesis services in the market. To leverage growth opportunities in the peptide synthesis market, Merck focuses on adopting organic as well as inorganic growth strategies.

Bachem holdings

Bachem is an important player in the peptide synthesis market in 2017. The company offers catalog products that include amino acids, resins, linkers, & reagents. It also offers custom synthesis services in the market. The company aims on broadening its geographic reach by investing in strategic acquisitions, agreements, and collaborations.

Peptide Synthesis Market: Impact Analysis of Drivers, Restraints, Opportunities, and Challenges

The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period. Factors such as the growing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers are expected to drive the growth of the market. However, the lack of a unified set of regulations for therapeutic peptides is expected to restrain the growth of this market during the forecast period.

Years considered for this report

# 2017 – Base Year

# 2018 – Estimated Year

# 2023 – Projected Year

Download the PDF Brochure for More Details@ http://bit.ly/2Mo8CfU


Objectives of the Study

• To define, describe, and forecast the peptide synthesis market on the basis of product, technology, end user, and region.
  
• To provide detailed information about factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).
  
• To strategically analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market.
  
• To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  
• To forecast the size of the market segments in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  
• To profile key players and comprehensively analyze their market shares and core competencies in the global peptide synthesis market.
  
• To track and analyze competitive developments such as partnerships, agreements, & collaborations; mergers & acquisitions; product developments; and geographical expansions in the global peptide synthesis market

Restraint:
Lack of A Unified Set of Regulations for Therapeutic Peptides

Opportunity:
Emerging Markets in the Asia Pacific Region

Challenge:
Issues Associated With the Route of Administration of Peptide Drugs

Research Methodology:

Top-down and bottom-up approaches were used to validate the size of the global peptide synthesis market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary sources secondary sources; directories; databases such as Hoovers, Bloomberg Businessweek, Factiva, and OneSource, journals and their market revenues were determined through primary and secondary research. Secondary research included the study of the annual and financial reports of top market players, whereas primary research included extensive interviews with the key opinion leaders such as CEOs, directors, and marketing executives. 

The percentage splits, shares, and breakdowns of the product markets were determined using secondary sources and verified through primary sources. All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data is consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Read the Detailed Article@ https://www.marketsandmarkets.com/Market-Reports/peptide-synthesis-market-158927365.html

The prominent players in the peptide synthesis market are GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGaA (Germany) and New England Peptide, Inc (US). Product launches and agreements, partnerships and collaborations were the major strategies adopted by these payers to maintain their positions in the peptide synthesis market.

Target Audience:

• Biotechnology & pharmaceutical companies
• Market research and consulting firms
• Venture capitalists and investors
• Research & development companies
• Contract research organizations (CROs)
• Academic research institutes
• Government institutes